sign in sign up
<<
Home , Abemaciclib, Blinatumomab, Cabozantinib, Carfilzomib, Cediranib, Cobimetinib

`All ETCTN Trials: Updated September 16, 2021 (Includes trials that are in review, approved, and active) CTEP Title Limited/ Radiation Disease Area(s) ClinicalTrials.gov website (if available) Trial ETCTN- Oncology ID wide 9466 Phase I/II Study of , ETCTN- Skin and other https://clinicaltrials.gov/ct2/show/NCT01989585 , and Navitoclax in wide BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I only) 9591 A Phase I Trial of Single Agent ETCTN- Solid tumors https://clinicaltrials.gov/ct2/show/NCT02070549 Trametinib (GSK1120212) in wide (no specified Advanced Cancer Patients with mutations) Hepatic Dysfunction 9673 A Multi-Institutional Phase 2 Study ETCTN- Gastrointestinal https://clinicaltrials.gov/ct2/show/NCT02314169 of or Nivolumab in wide Combination with in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal 9881 A Phase 2 Study of in ETCTN- Breast, https://clinicaltrials.gov/ct2/show/NCT02498613 Combination with in wide Gastrointestinal, Advanced Solid Tumors Lung 9892 Phase I Dose-Escalation ETCTN- Radiation Gynecologic https://clinicaltrials.gov/ct2/show/NCT02595879 Study of Oral wide Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer 9914 A Phase I Study of a Combination Limited Solid tumors https://clinicaltrials.gov/ct2/show/NCT02631733 of MM-398 and in Solid (no specified Tumors mutations) 9924 A Phase I Trial of the Combination ETCTN- https://clinicaltrials.gov/ct2/show/NCT02568553 of and wide in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL) 9938 Phase I of VX-970 in Limited Solid tumors https://clinicaltrials.gov/ct2/show/NCT02595931 Combination with the (no specified I Inhibitor mutations) in Patients with Advanced Solid Tumors 9950 A Phase I Study of M6620 (VX- ETCTN- Radiation Head and https://clinicaltrials.gov/ct2/show/NCT02567422 970) in Combination with wide Neck/Thyroid and XRT in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121) 9979 Phase 1 and Pharmacology Study of ETCTN- Radiation Brain https://clinicaltrials.gov/ct2/show/NCT02993146 Oral 5-Iodo-2-Pyrimidinone-2- wide Deoxyribose (IPdR) as a for IUdR-Mediated Tumor Radiosensitization in Brain Metastases 10014 A Pilot Study of ETCTN- , https://clinicaltrials.gov/ct2/show/NCT02862275 (MPDL3280A) Following Adoptive wide Lymphoma, Cell Transfer in Active Solid tumors Hematologic or Solid Tumor (no specified Malignancies mutations) 10020 A Phase II Open-Label, ETCTN- Breast https://clinicaltrials.gov/ct2/show/NCT02849496 Randomized Study of PARP wide Inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive 10026 A Phase 1 Study of Ipilimumab in Limited Leukemia https://clinicaltrials.gov/ct2/show/NCT02890329 Combination with in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia 10030 A Phase 1 Study of Blinatumomab Limited Leukemia https://clinicaltrials.gov/ct2/show/NCT02879695 in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B- lymphoblastic Leukemia 10056 A Phase 2 Study of Talimogene ETCTN- Radiation https://clinicaltrials.gov/ct2/show/NCT02923778 Laherparepvec (T-VEC) and wide Radiation in Localized Soft Tissue Sarcoma 10057 A Phase II Study of Talimogene ETCTN- Skin and other https://clinicaltrials.gov/ct2/show/NCT02978625 Laherparepvec Followed by wide melanoma Talimogene Laherparepvec + Nivolumab in Refractory and NK Cell , Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors 10058 A Phase I Study of Talimogene Limited Radiation Gastrointestinal https://clinicaltrials.gov/ct2/show/NCT03300544 Laherparepvec (TALIMOGENE LAHERPAREPVEC) with Neoadjuvant and Radiation in Adenocarcinoma of the Rectum 10061 A Phase 1 Study of ETCTN- Solid tumors https://clinicaltrials.gov/ct2/show/NCT03030378 (MK-3475) in Combination with wide (no specified Recombinant -12 in mutations) Patients with Solid Tumors 10066 A Phase 1/2 Study of Olaparib in ETCTN- Gastrointestinal https://clinicaltrials.gov/ct2/show/NCT03008278 Combination with in wide Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760) 10075 A Phase 1B Study of KRT-232 ETCTN- Leukemia https://clinicaltrials.gov/ct2/show/NCT03041688 (AMG-232) in Combination with wide Decitabine in Acute Myeloid Leukemia 10076 A Phase 1 Dose-Escalation and Limited Myeloma https://clinicaltrials.gov/ct2/show/NCT03031730 Exploratory Dose Expansion Study of AMG 232 in Combination with , Lenalidomide, and in Relapsed and/or Refractory Myeloma 10089 A Randomized Phase 2 Study of ETCTN- Lymphoma https://clinicaltrials.gov/ct2/show/NCT03038672 CDX-1127 (Varlilumab) in wide Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas 10096 A Phase 1/2 Study of Combination ETCTN- Radiation Genitourinary https://clinicaltrials.gov/ct2/show/NCT03317392 Olaparib and Radium-223 in Men wide with Metastatic Castration-Resistant with Bone Metastases (COMRADE) 10100 A Randomized, Phase 2 Trial to ETCTN- Genitourinary https://clinicaltrials.gov/ct2/show/NCT03237780 Evaluate the Safety and Efficacy of wide Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin- Based Treatment is Not an Option 10107 Phase 1 Safety Run-In and Phase 2 ETCTN- Lung https://clinicaltrials.gov/ct2/show/NCT03126630 Randomized Clinical Trial of wide Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab (MK- 3475) Alone for Mesothelin- Positive Malignant Pleural Mesothelioma 10126 A Pilot Phase I Study of ETCTN- Lymphoma https://clinicaltrials.gov/ct2/show/NCT03321643 Atezolizumab (MPDL3280A) in wide Combination with Immunogenic Chemotherapy (- ) and for Transformed Diffuse Large B-Cell Lymphoma 10129 A Phase 2 Study of the PARP ETCTN- Brain, https://clinicaltrials.gov/ct2/show/NCT03212274 Inhibitor Olaparib (AZD2281) in wide Gastrointestinal, IDH1 and IDH2 Mutant Advanced Solid tumors Solid Tumors (mutations) 10131 Phase I Study of AZD8186 in Limited Breast, https://clinicaltrials.gov/ct2/show/NCT03218826 Combination with in Genitourinary, Patients with PTEN Mutated or Solid tumors PIK3CB Mutated Advanced Solid (mutations; Tumors, Potentially Amenable to escalation only) Docetaxel 10136 A Phase 2 Trial of AZD1775, a ETCTN- Solid tumors https://clinicaltrials.gov/ct2/show/NCT03253679 Wee1 Inhibitor, in Patients with wide (mutations) CCNE1 Amplification 10144 A Phase II Study of Olaparib ETCTN- Genitourinary https://clinicaltrials.gov/ct2/show/NCT03375307 (AZD2281) in Patients with wide Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects 10146 Randomized phase 2 clinical trial of ETCTN- Breast https://clinicaltrials.gov/ct2/show/NCT03606967 nab-paclitaxel + MEDI4736 wide () + tremelimumab + neoantigen vaccine vs. nab- + MEDI4736 (durvalumab) + tremelimumab in patients with metastatic triple negative breast cancer 10150 A Randomized Phase 2 Study of ETCTN- Gynecologic https://clinicaltrials.gov/ct2/show/NCT03587311 and Either Weekly wide Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory 10166 A Phase 2 Study of Atezolizumab ETCTN- Lung https://clinicaltrials.gov/ct2/show/NCT03600701 and in PD-1/PD-L1 wide Inhibitor Resistant or Refractory Non-Small Cell 10170 A Phase 2 Study of AZD1775 in ETCTN- Solid tumors https://clinicaltrials.gov/ct2/show/NCT03284385 SETD2-Deficient Advanced Solid wide (mutations) Tumor Malignancies 10181 A Phase II Study of in ETCTN- Gastrointestinal https://clinicaltrials.gov/ct2/show/NCT03592641 Subjects with MET Amplified wide Metastatic 10183 A Pilot Study of Tazemetostat and ETCTN- Genitourinary https://clinicaltrials.gov/ct2/show/NCT03854474 Pembrolizumab (MK-3475) in wide Advanced Urothelial Carcinoma 10184 Birinapant and Intensity Modulated ETCTN- Radiation Head and https://clinicaltrials.gov/ct2/show/NCT03803774 Re-Irradiation Therapy (IMRRT) wide Neck/Thyroid for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) 10186 A Phase I/II Study of Nivolumab ETCTN- Radiation Brain https://clinicaltrials.gov/ct2/show/NCT03604978 Plus or Minus Ipilimumab in wide Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation- Relapsed Meningioma 10193 Phase 2 Study of in ETCTN- Lymphoma https://clinicaltrials.gov/ct2/show/NCT03484819 Combination with Nivolumab in wide Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B- Cell Lymphoma 10195 A Phase 2 Study of Copanlisib ETCTN- Breast https://clinicaltrials.gov/ct2/show/NCT03803761 (BAY 80-6946) in Combination wide with in Women with Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor 10204 Phase Ib Study of Nivolumab in ETCTN- Solid tumors https://clinicaltrials.gov/ct2/show/NCT03816345 Patients with Autoimmune wide (no specified Disorders and Advanced mutations), Malignancies (AIM-NIVO) Lymphoma 10208 A Phase I/II study of Anetumab ETCTN- Gastrointestinal https://clinicaltrials.gov/ct2/show/NCT03816358 Ravtansine in Combination with wide Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin- Positive Advanced Pancreatic Adenocarcinoma 10211 A Phase 2 Single-Arm Study of ETCTN- Gastrointestinal https://clinicaltrials.gov/ct2/show/NCT03641313 M6620 in Combination with wide Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer 10214 Immune Checkpoint Blockade for ETCTN- Skin and other https://clinicaltrials.gov/ct2/show/NCT03816332 Kidney Transplant Recipients with wide melanoma Selected Unresectable or Metastatic Cancers 10216 A Phase Ib/II Study of ETCTN- Lung https://clinicaltrials.gov/ct2/show/NCT03831932 and CB-839 in Patients with EGFR wide Mutant Non-Small Cell Lung Cancer 10217 A Phase 1b Biomarker-Driven Limited Solid tumors https://clinicaltrials.gov/ct2/show/NCT03842228 Combination Trial of Copanlisib, (mutations) Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors 10218 A Phase Ib Trial of CB-839 in ETCTN- Radiation Brain https://clinicaltrials.gov/ct2/show/NCT03528642 Combination with Radiation wide Therapy and in Patients with IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma 10219 Phase I Dose-Escalation and Dose- ETCTN- Myeloma https://clinicaltrials.gov/ct2/show/NCT03798678 Expansion Trial of a Novel wide Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory 10220 A Phase II Basket Trial of ETCTN- Solid tumors https://clinicaltrials.gov/ct2/show/NCT03872427 Glutaminase Inhibitor (BeGIN) CB- wide (mutations), 839 HCl in Patients with NF1 Brain Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors 10221 Phase I/II Biomarker-Driven Limited Solid tumors https://clinicaltrials.gov/ct2/show/NCT04317105 Combination Trial of Copanlisib (Phase 1 (mutations) and Immune Checkpoint Inhibitors only) in Patients with Advanced Solid Tumors 10222 A Phase II Study of Olaparib and ETCTN- Gastrointestinal, https://clinicaltrials.gov/ct2/show/NCT03878095 AZD6738 in Isocitrate wide Solid tumors Dehydrogenase (IDH) Mutant Solid (mutations) Tumors 10237 A Phase 1 Study of TAK-243 for ETCTN- Leukemia https://clinicaltrials.gov/ct2/show/NCT03816319 Either Relapsed/Refractory Acute wide Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents 10240 Phase II Study of XL184 ETCTN- Head and https://clinicaltrials.gov/ct2/show/NCT03914300 (Cabozantinib) in Combination with wide Neck/Thyroid, Nivolumab and Ipilimumab endocrine (CaboNivoIpi) in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR- 10246 A Phase 1 Study of MLN4924 Limited Leukemia https://clinicaltrials.gov/ct2/show/NCT03772925 (Pevonedistat) and in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome 10249 MLN9708 () and ETCTN- Myeloma https://clinicaltrials.gov/ct2/show/NCT03770260 MLN4924 (Pevonedistat) in wide Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial 10264 The PRIME Trial: PARP Inhibition ETCTN- Leukemia https://clinicaltrials.gov/ct2/show/NCT03953898 in IDH Mutant Effectiveness Trial. wide A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome 10268 Randomized Phase II Trial of ETCTN- Lung https://clinicaltrials.gov/ct2/show/NCT03896503 Plus M6620 (VX-970, wide Berzosertib) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer 10273 A Phase I Study of M3814 in ETCTN- Leukemia https://clinicaltrials.gov/ct2/show/NCT03983824 Combination with MEC in Patients wide with Relapsed or Refractory Acute Myeloid Leukemia 10276 A Phase I/II Study of M3814 and Limited Radiation Gastrointestinal, https://clinicaltrials.gov/ct2/show/NCT04068194 in Combination with (Phase 1) Solid tumors Hypofractionated Radiation in (dose Patients with Advanced/Metastatic escalation) Solid Tumors and Hepatobiliary Malignancies 10285 Phase 1/2 Study of an EZH2 ETCTN- Skin and other https://clinicaltrials.gov/ct2/show/NCT04557956?id=10285 Inhibitor (Tazemetostat) in wide melanoma Combination with Dual BRAF/MEK Inhibition in Patients with BRAF- Mutated Metastatic Melanoma who Progressed on Prior BRAF/MEK Inhibitor Therapy 10287 A Randomized Phase I/II Trial of ETCTN- Breast https://clinicaltrials.gov/ct2/show/NCT03939897 Fulvestrant and in wide Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine Re sistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA) 10291 A Phase 1b Study of M6620 in ETCTN- Radiation Breast https://clinicaltrials.gov/ct2/show/NCT04052555 Combination with Radiation wide Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer 10292 DURVA+ : Evaluation of the ETCTN- Solid tumors https://clinicaltrials.gov/ct2/show/NCT03907475 Safety and of wide (no specified Anti-PD-L1 Antibody MEDI4736 mutations) (Durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors 10296 Phase Ib/II Trial of Copanlisib in Limited Breast https://clinicaltrials.gov/ct2/show/NCT04108858 Combination with and (Phase 1) After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) with PIK3CA Mutation or PTEN Mutation 10299 A Phase I Study to Investigate the ETCTN- Lymphoma, Not available at this time. Safety of the Ubiquitin Activating wide Solid tumors Inhibitor TAK-243 in (no specified Adult Solid Tumor and Lymphoma mutations) Patients 10300 BLAST MRD AML-1: A ETCTN- Leukemia https://clinicaltrials.gov/ct2/show/NCT04214249 Randomized Phase 2 Study of the wide Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia 10301 A Phase I and Randomized Phase II ETCTN- Radiation Genitourinary https://clinicaltrials.gov/ct2/show/NCT04071236 Trial of Radium-223 Dichloride, wide M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) 10302 Phase II Trial of Radium-223 ETCTN- Radiation Breast https://clinicaltrials.gov/ct2/show/NCT04090398 Dichloride in Combination with wide Paclitaxel in Patients with Bone Metastatic Breast Cancer 10313 A Phase IB and Randomized Open- ETCTN- Lung https://clinicaltrials.gov/ct2/show/NCT04216316 Label Phase II Study of M6620 in wide Combination with /Gemcitabine/Avelumab in Patients with Chemotherapy- Naive Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology 10315 A Phase II Study of XL184 ETCTN- Solid tumors https://clinicaltrials.gov/ct2/show/NCT04079712 (Cabozantinib) in Combination with wide (no specified Nivolumab and Ipilimumab for the mutations), Treatment of Poorly Differentiated endocrine Neuroendocrine Carcinomas 10317 A Pilot Study of Nivolumab in Limited Leukemia https://clinicaltrials.gov/ct2/show/NCT04277442 Combination with Decitabine and in TP53-Mutated Acute Myeloid Leukemia 10324 A Phase I/Ib Dose Escalation Study Limited Gynecologic https://clinicaltrials.gov/ct2/show/NCT04092270 of Pegylated Liposomal (PLD) with M3814 in Platinum - Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) 10327 A Phase I Trial of MLN0128(TAK- Limited Lung https://clinicaltrials.gov/ct2/show/NCT04250545 228) and CB-839 HCL (telaglenastat) in Advanced NSCLC Patients 10329 Phase I Sequential Trial of Agents Limited Solid tumors https://clinicaltrials.gov/ct2/show/NCT04197713 Against DNA Repair (STAR) (Phase 1 (mutations) only) 10330 A Phase 2 Study of Belinostat and ETCTN- Sarcoma https://clinicaltrials.gov/ct2/show/NCT04340843 SGI-110 (Guadecitabine) for the wide Treatment of Unresectable and Metastatic Conventional Chondrosarcoma 10334 BLAST MRD AML-2: A ETCTN- Leukemia https://clinicaltrials.gov/ct2/show/NCT04284787 Randomized Phase 2 Study of wide Venetoclax, Azacitadine, and Pembrolizumab Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia Who Are Ineligible or Who Refuse Intensive Chemotherapy 10335 A Phase 1 Study of Lenalidomide in ETCTN- Leukemia, https://clinicaltrials.gov/ct2/show/NCT04301076 Combination with EPOCH wide Lymphoma Chemotherapy for HTLV- Associated Adult T-Cell Leukemia- Lymphoma (ATLL) 10346 Pilot Study of DS-8201a Limited Solid tumors https://clinicaltrials.gov/ct2/show/NCT04294628 Pharmacodynamics in Patients with (mutations) HER2-Expressing Advanced Solid Tumors 10347 A phase I study with an expansion ETCTN- Lymphoma https://clinicaltrials.gov/ct2/show/NCT04652960?id=10347&draw=2&rank=1 cohort of and nivolumab wide in mycosis fungoides (MF) and Sézary syndrome (SS) 10355 A Phase I Study of DS-8201a in ETCTN- Solid tumors https://clinicaltrials.gov/ct2/show/NCT04585958 Combination with Olaparib in wide (mutations), HER2-Expressing Malignancies solid tumor dose escalation, gynecologic 10358 Phase 1/1B study of DS8201a in ETCTN- Gastrointestinal, https://clinicaltrials.gov/ct2/show/NCT04704661 combination with ATR Inhibition wide Solid tumors (AZD6738) in advanced solid (dose tumors with HER2 expression escalation) (DASH Trial) 10366 A Phase 1/2 Study of M3814 ETCTN- Radiation Gastrointestinal https://clinicaltrials.gov/ct2/show/NCT04172532 (Peposertib) in Combination with wide Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma 10367 A Phase 1b Study with Expansion ETCTN- Leukemia https://clinicaltrials.gov/ct2/show/NCT04190550 Cohort of Escalating Doses of wide KRT-232 (AMG 232) Administered in Combination with Standard Induction Chemotherapy ( and ) in Newly Diagnosed Acute Myelogenous Leukemia (AML) 10371 A Pharmacodynamics-Driven Trial Limited Solid tumors https://clinicaltrials.gov/ct2/show/NCT04550494 of , an Oral PARP (mutations) Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response 10382 A Phase I/II Trial Evaluating the Limited Breast https://clinicaltrials.gov/ct2/show/NCT04345913 Safety and Efficacy of Eribulin in (Phase 1) Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer 10384 A Phase 1b/2 Study of Hu5F9-G4 ETCTN- Lymphoma https://clinicaltrials.gov/ct2/show/NCT04541017 (Magrolimab) in Combination with wide in Relapsed/Refractory Treated T-Cell Lymphoma 10387 Pilot Trial of Nivolumab Plus Limited Sarcoma, Solid https://clinicaltrials.gov/ct2/show/NCT04514484 Cabozantinib for Advanced Solid tumors (dose Tumors in Patients with HIV escalation) 10388 A Phase I Trial of Triapine and ETCTN- Radiation Gastrointestinal, https://clinicaltrials.gov/ct2/show/NCT04234568 Lutetium Lu 177 Dotatate in wide endocrine Combination for Well- Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP- NETs) 10389 A Phase 1 Trial Combining WEE1 ETCTN- Radiation Gastrointestinal https://clinicaltrials.gov/ct2/show/NCT04460937 Inhibitor Adavosertib (AZD1775) wide with Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer

10398 A Phase 2 Study of Anti-PD-L1 ETCTN- Sarcoma https://clinicaltrials.gov/ct2/show/NCT04458922 Antibody (Atezolizumab) in wide Chondrosarcoma and Clear Cell Sarcoma 10399 A Phase 1 Study of in ETCTN- Lung https://clinicaltrials.gov/ct2/show/NCT04631029?id=10399 Combination with Atezolizumab / wide Carboplatin / in Previously Untreated Extensive- Stage Small Cell Lung Cancer 10401 A Phase 0 window-of-opportunity ETCTN- Gynecologic https://clinicaltrials.gov/ct2/show/NCT04494113 pharmacodynamic trial of triapine wide (NSC# 663249) in uterine corpus serous adenocarcinoma

10402 BAY1895344 Plus Topoisomerase- ETCTN- Gastrointestinal, https://clinicaltrials.gov/ct2/show/NCT04514497 1 (Top1) Inhibitors in Patients with wide Lung, Solid Advanced Solid Tumors, Phase I tumors (dose Studies with Expansion Cohorts in escalation), Small Cell Lung Carcinoma endocrine (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD- NEC) and Pancreatic Adenocarcinoma (PDA)

10403 Phase 1 Trial of Gemcitabine ETCTN- Gastrointestinal, https://clinicaltrials.gov/ct2/show/NCT04616534 Combined with the BAY1895344 wide Gynecologic, ATR Inhibitor with Expansion Solid Tumors Cohorts in Advanced Pancreatic (dose and Ovarian Cancer escalation) 10404 A Phase I Trial of the ATR ETCTN- Genitourinary, https://clinicaltrials.gov/ct2/show/NCT04491942 Inhibitor BAY 1895344 in wide Solid tumors Combination with Cisplatin and (dose with Cisplatin Plus Gemcitabine in escalation) Advanced Solid Tumors with an Emphasis on Urothelial Carcinoma 10405 Phase 1 Trial of BAY1895344 ATR ETCTN- Head and Neck https://clinicaltrials.gov/ct2/show/NCT04576091 Inhibitor Combined with wide Cancer, Stereotactic Body Radiation Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma 10406 Phase 1/1b Trial of ATR Inhibitor ETCTN- Gastrointestinal https://clinicaltrials.gov/ct2/show/NCT04535401 BAY 1895344 in Combination with wide FOLFIRI in GI malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers 10410 A Phase 1 Study of IPdR in ETCTN- Radiation Gastrointestinal https://clinicaltrials.gov/ct2/show/NCT04406857 Combination with and wide Radiotherapy in Rectal Cancer 10411 Phase 2 Study of Rogaratinib (BAY Limited Sarcoma https://clinicaltrials.gov/ct2/show/NCT04595747 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST) 10422 Abemaciclib and Olaparib for ETCTN- Gynecologic https://clinicaltrials.gov/ct2/show/NCT04633239?id=10422 Recurrent Ovarian Cancer wide

10437 A Single Arm Phase II Study of ETCTN- Radiation Genitourinary https://clinicaltrials.gov/ct2/show/NCT04616547?id=10437 Bone-Targeted Sn-117m-DTPA in wide Symptomatic Castration Resistant Prostate Cancer with Skeletal Metastases 10417 Clinical Evaluation of ASTX727 in ETCTN- Leukemia https://clinicaltrials.gov/ct2/show/NCT04817241 Combination with Venetoclax All- wide Oral Therapy vs Standard of Care Cytarabine and Induction Chemotherapy for Younger FLT3WT Patients with ELN High- Risk Acute Myeloid Leukemia 10450 A Phase 1b Study of M3814 ETCTN- Gastrointestinal https://clinicaltrials.gov/ct2/show/NCT04750954 (Peposertib) in Combination with wide Lutetium 177 Dotatate in Well- Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP- NETs) 10434 Randomized Phase 2 Study of ETCTN- Leukemia https://clinicaltrials.gov/ct2/show/NCT04802161 CPX-351 + Pomalidomide versus wide CPX-351 in Newly Diagnosed AML with MDS-Related Changes 10433 Phase I/Ib trial evaluating the safety Limited Solid tumors https://clinicaltrials.gov/ct2/show/NCT04840589 and efficacy of BET inhibitor, (no specified ZEN003694 with PD-1 inhibitor, mutations), nivolumab with or without CTLA-4 Gynecologic inhibitor, ipilimumab in solid tumors 10440 A Phase 1/1a Study of Venetoclax, Limited Myeloma https://clinicaltrials.gov/ct2/show/NCT04847453 MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis

10466 A Phase II Study of Bevacizumab, Limited Genitourinary https://clinicaltrials.gov/ct2/show/NCT04981509 and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer 10476 A Randomized Phase 2 Study of ETCTN- Gastrointestinal https://clinicaltrials.gov/ct2/show/NCT04941287 combination Atezolizumab and wide Varlilumab with or without addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers 10483 Phase Ib Trial of ETCTN- Genitourinary https://clinicaltrials.gov/ct2/show/NCT04963153 Combined with Enfortumab wide Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations 10445 Phase I Dose Escalation and ETCTN- Lung Not available at this time. Expansion Study of Tazemetostat in wide Combination with Topotecan and Pembrolizumab in Extensive-Stage Small Cell Lung Cancer 10499 Phase Ib/II Study of ZEN003694 ETCTN- Lymphoma Not available at this time. and Entinostat in Advanced and wide Refractory Solid Tumors and Lymphomas 10507 A Phase 1/2 Study of the ETCTN- Sarcoma https://clinicaltrials.gov/ct2/show/NCT05019716 Bromodomain Inhibitor wide ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma 10490 Rapid Analysis and Response ETCTN- Solid tumors Not available at this time. Evaluation of Combination Anti- wide (no specified Neoplastic Agents in Rare Tumors mutations) (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide 10492 Phase I/Ib Study of AKT Inhibitor ETCTN- Radiation Head and Not available at this time. Ipatasertib with Chemoradiation for wide neck/radiation Locally Advanced Head and Neck Cancer 10496 A Phase II Trial of Ipatasertib in ETCTN- Head and neck Not available at this time. Combination with Pembrolizumab wide for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck 10486 Phase 2 Trial of the Combination of ETCTN- Solid tumors Not available at this time. the BET Inhibitor, ZEN-3694, and wide (no specified the PARP Inhibitor Talazoparib, in mutations) Patients with Molecularly-Selected Solid Tumors (ComBET) 10495 Phase I Trial of DS-8201a ETCTN- Solid tumors Not available at this time. () in wide (no specified Combination with in mutations) Solid Tumors with HER2 Alterations 10504 Atezolizumab with or Without Limited Sarcoma Not available at this time. or with IxazOMib in Alveolar Soft Part Sarcoma (AXIOM) 10508 A Phase 1 Study of Nivolumab in ETCTN- Lymphoma Not available at this time. Combination with ASTX727 in B- wide cell lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) 10449 A Phase 1 Study of ZEN003694 in Limited Breast Not available at this time. Combination with in (for dose Solid Tumors with RAS Pathway escalation) Alterations and Triple Negative Breast Cancer

10480 Phase Ib/II Study of EPA-Based Limited Breast Not available at this time. EphA2 Targeted Therapy for (for Phase Patients with Metastatic Triple- Ib) Negative Inflammatory Breast Cancer 10509 A Phase 1 Study of BET ETCTN- ST no specified Not available at this time. Bromodomain Inhibitor wide mutations ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors 10512 BER Inhibitor TRC102 Added to Limited Lung Not available at this time. Standard -Platinum- Radiation in Stage III Non- Squamous Non-Small Cell Lung Cancer New!!